Get the Stockscreener App
7.675
2.53%
-0.205
Zevra Therapeutics Inc stock is traded at $7.675, with a volume of 96,286.
It is down -2.53% in the last 24 hours and down -6.79% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$7.88
Open:
$7.87
24h Volume:
96,286
Relative Volume:
0.19
Market Cap:
$420.60M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-5.9496
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-2.03%
1M Performance:
-6.79%
6M Performance:
+6.09%
1Y Performance:
+32.20%
1-Day Range:
$7.65
$7.92
1-Week Range:
$7.4801
$8.334
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.675 | 420.60M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.22 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.51 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Hypersomnia Pipeline 2024: MOA, ROA, and Clinical Trial - openPR
BlackRock, Inc. Increases Stake in Zevra Therapeutics Inc. - GuruFocus.com
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Janney Montgomery Scott LLC Has $2.48 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy” - Defense World
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - GlobeNewswire
Breakthrough Treatment for Rare Brain Disease: Zevra's MIPLYFFA Earns Major Industry Recognition - StockTitan
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Rare Disease Leader Zevra Takes Center Stage at Major Healthcare Investment Events - StockTitan
Cantor Fitzgerald Predicts ZVRA FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ZVRA FY2025 Earnings - MarketBeat
Objective long/short (ZVRA) Report - Stock Traders Daily
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $21.57 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts - Defense World
Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock - Yahoo Finance
Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings - Defense World
Learn to Evaluate (ZVRA) using the Charts - Stock Traders Daily
FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $7.25 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
Sanctuary Advisors LLC Trims Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Sanctuary Advisors LLC Has $194,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00 - MarketBeat
13,551 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by XTX Topco Ltd - Defense World
(ZVRA) Investment Analysis and Advice - Stock Traders Daily
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - The Manila Times
Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following Transformative Year - StockTitan
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Fmr LLC Acquires 2,312,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Restructures to Focus on Rare Diseases - MSN
A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - PharmaVoice
Zevra Therapeutics Announces Organizational Changes - The Manila Times
Zevra Therapeutics, Inc. Announces Departure of Executives - Marketscreener.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.00 Consensus Price Target from Brokerages - MarketBeat
Vestal Point Capital LP Purchases Shares of 525,000 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC - MarketBeat
Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Clifton R. LaDuane | CFO & Treasurer |
Jul 17 '24 |
Buy |
6.77 |
2,000 |
13,540 |
18,469 |
| Anderson Thomas | Director |
Jul 16 '24 |
Buy |
6.81 |
10,000 |
68,065 |
20,000 |
| Bode John B | Director |
Jul 12 '24 |
Buy |
5.87 |
10,000 |
58,661 |
30,000 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):